Parameter
| Biomarker | APOE+ITIH3+APOA1+APOL1+CA19-9 (joint panel) | Full name | Apolipoprotein E + Inter-alpha-trypsin inhibitor heavy chain H3 + Apolipoprotein A1 + Apolipoprotein L1 + CA19-9 | Molecular Type | Protein combination |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Protein combination | ||
| Disease | Protein combination | Disease Subtypes | / | ||
| Organ | Pancreas | Test Sample / Technology Platform | Serum (Mass spectrometry, immunoassay) | ||
| Pathobiological Mechanisms | It includes members of the apolipoprotein and protease inhibitors family, which are involved in the regulation of lipid metabolism and inflammatory response. The combination of these two proteins can improve the diagnostic specificity and sensitivity | ||||
| Clinical Availability Status | Clinical research phase: validation in multiple populations, diagnostic sensitivity 95%, specificity 94.1% | ||||
| Notes and Dynamics | It can effectively distinguish early PDAC from pancreatitis, solve the problem of insufficient specificity of single marker, and is suitable for high-risk population screening | ||||